

Patient representation and participation

EFCCA is an international organisation that represents 46 national Crohn's and Ulcerative Colitis patient associations. We are united in our commitment to improve the life of over 10 million people living with IBD worldwide (3.4 million in Europe alone) and to give them a louder voice and more visibility.

EFCCA's involvement in the GENEGUT project provides valuable insights into the patient experience and helps to ensure that the therapy being developed is patient-centered. At the same time we can ensure that the patient's perspective is integrated into the various components of the overall project.

EFCCA will also play an important role in raising awareness about the GENEGUT project and the potential benefits it could bring to people with Crohn's disease. Patients' feedback will be crucial in ensuring that the therapy developed meets the needs of those living with Crohn's Disease. Together, we can create a better future!



Follow the GENEGUT project



www.genegut.eu



@GENEGUT_EU

GENEGUT

Oral RNA-based therapy for Crohn's Disease

Factsheet for patients



Funded by the European Union

Funded by the European Union (GA 101057491). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.



Innovate UK

UK participants in Horizon Europe Project GENEGUT are supported by UKRI grant number 10042451 (Bangor University)

What is GENEGUT?

About

GENEGUT is a research project funded by the European Commission to develop a new medicine for ileal Crohn's Disease.



GENEGUT brings together 9 partners from 8 European countries, and includes a patient association, renowned researchers, expert clinical scientists, SMEs and large pharma companies.



GENEGUT is a 4-year Horizon Europe Research and Innovation project, funded with 5.4 million Euro and coordinated by the University College Cork, Ireland.

“The treatment of Crohn's Disease remains a big unmet clinical need - this is what GENEGUT is trying to solve”

Prof. Caitriona O'Driscoll
GENEGUT project coordinator



What is the GENEGUT medicine and how is it different from existing forms of treatment?

The GENEGUT therapy will be a new type of medicine, that will help people with a specific type of Crohn's Disease that affects the ileum (i.e. the last section of the small intestine that connects to the large intestine). This medicine helps the mRNA to act directly at the affected area in the intestine, which means that the rest of the body is less likely to be affected and thus help reduce side effects.

Will GENEGUT include a clinical study and can I participate in it?


At the moment there is no clinical trial study that you can participate in as part of GENEGUT. The GENEGUT project will include the development of a clinical trial protocol for a human clinical study involving ileal Crohn's Disease patients. While the GENEGUT partners envision the adoption of this clinical trial protocol in a follow-up project, it is not included as part of GENEGUT.

When will the GENEGUT medicine be available?

The GENEGUT medicine is the long-term goal of the project, aiming to be realised within 7-10 years after the project's end, with the foreseen regulatory acceptance and market entry.

RNA therapy

Messenger RNA (mRNA) is a natural substance that is found in all human cells. Its job is to carry instructions from our genes to our cells, telling them how to make proteins. In GENEGUT, mRNA is used to make therapeutic proteins that can help slow down the progression of Crohn's Disease.



RNA therapeutics have the potential to treat a wide range of different, previously hard to treat, diseases once the technology to safely and effectively deliver the RNA to the disease site is optimized.

Questions? Reach out to us: www.genegut.eu/contact